Prostate Cancer as a Model System for Genetic Diversity in Tumors

Advances in Cancer Research

Volumn 112, Issue , 2011, Pages 183-216

  Squire, Jeremy A ^a   Park, Paul C ^a   Yoshimoto, Maisa ^a   Alami, Jennifer ^a   Williams, Julia L ^a   Evans, Andrew ^b   Joshua, Anthony M ^c,d  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Gene fusion; Heterogeneity; Oncogenomics; Preneoplasia; Prostate cancer; Rearrangement

Indexed keywords

ANDROGEN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR;

ANDROGEN RELEASE; BOOK; CARCINOGENESIS; CELL STRUCTURE; CHROMOSOMAL INSTABILITY; DISEASE COURSE; ETS GENE; FUSION GENE; GENE DELETION; GENE FREQUENCY; GENE LOSS; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOMIC INSTABILITY; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; MOLECULAR MODEL; MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; STEM CELL; STROMA CELL; TELOMERE; TMPRSS2 GENE;

EID: 80053044469     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387688-1.00007-7     Document Type: Chapter

References (208)

1. Afar D.E., Vivanco I., Hubert R.S., Kuo J., et al. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res. 2001, 61(4):1686-1992.
2. Ai J., Wang Y., Dar J.A., Liu J., et al. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol. Endocrinolo 2009, 23(12):1963-1972.
3. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Nat. Acad. Sci. USA 2003, 100(7):3983-3988.
4. Albadine R., Latour M., Toubaji A., Haffner M., et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod. Pathol. 2009, 22(11):1415-1422.
5. Alimonti A., Carracedo A., Clohessy J.G., Trotman L.C., et al. Subtle variations in Pten dose determine cancer susceptibility. Nat. Genet. 2010, 42(5):454-458.
6. Allsbrook W.C., Mangold K.A., Yang X., Epstein J.I. The Gleason grading system: an overview. J. Urol. Pathol. 1999, 10:141-157.
7. SEER Cancer Statistics Review, 1975-2007 2009, Bethesda, MD. S.F. Altekruse, C.L. Kosary, M. Krapcho, N. Neyman, R. Aminou, W. Waldron, J. Ruhl, N. Howlader, Z. Tatalovich, H. Cho, A. Mariotto, M.P. Eisner, D.R. Lewis, K. Cronin, H.S. Chen, E.J. Feuer, D.G. Stinchcomb, B.K. Edwards (Eds.).
8. Ananthanarayanan V., Deaton R.J., Yang X.J., Pins M.R., Gann P.H. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer. Prostate 2005, 63(4):341-346.
9. Ananthanarayanan V., Deaton R.J., Yang X.J., Pins M.R., Gann P.H. Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer 2006, 6:73.
10. Andreoiu M., Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Human Pathology 2010, 41:781-793.
11. Anton R.C., Kattan M.W., Chakraborty S., Wheeler T.M. Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. Amer. J. Surg. Pathol. 1999, 23(8):932-936.
12. Arora R., Koch M.O., Eble J.N., Ulbright T.M., et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004, 100(11):2362-2366.
13. Attard G., Clark J., Ambroisine L., Fisher G., et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27(3):253-263.
14. Attard G., Clark J., Ambroisine L., Mills I.G., et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br. J. Cancer. 2008, 99(2):314-320.
15. Attard G., Jameson C., Moreira J., Flohr P., et al. Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. J. Clin. Pathol. 2009, 62(4):373-376.
16. Ayala A.G., Ro J.Y. Prostatic intraepithelial neoplasia: recent advances. Arch. Path. Lab. Med. 2007, 131(8):1257-1266.
17. Ayala G., Thompson T., Yang G., Frolov A., et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin. Cancer Res. 2004, 10(19):6572-6578.
18. Balk S.P., Knudsen K.E. AR, the cell cycle, and prostate cancer. Nucl. Receptor Signaling 2008, 6:e001.
19. Bartels P.H., Silva V.D., da Montironi R., Hamilton P.W., et al. Chromatin texture signatures in nuclei from prostate lesions. Anal. Quant. Cytology Histology. 1998, 20(5):407-416.
20. Barwick B., Abramovitz M., Kodani M. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. J Cancer. 2010, 102(3):570-576.
21. Basuyaux J.P., Ferreira E., Stéhelin D., Butticè G. The ETS transcription factors interact with each other and with the c-Fos/c-JUN complex via distinct protein domains in a DNA-dependent and -independent manner. J Biol. Chem. 1997, 272(42):26188-26195.
22. Bednarz N., Eltze E., Semjonow A., Rink M., et al. BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin. Cancer Res. 2010, 16(13):3340-3348.
23. Beheshti B., Vukovic B., Marrano P., Squire J.A., Park P.C. Resolution of genotypic heterogeneity in prostate tumors using polymerase chain reaction and comparative genomic hybridization on microdissected carcinoma and prostatic intraepithelial neoplasia foci. Cancer Gen. Cytogen. 2002, 137(1):15-22.
24. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., et al. The genomic complexity of primary human prostate cancer. Nature. 2011, 470(7333):214-220.
25. Bethel C.R., Faith D., Li X., Guan B., et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res. 2006, 66(22):10683-10690.
26. Billis A. Prostatic atrophy: an autopsy study of a histologic mimic of adenocarcinoma. Mod. Pathol. 1998, 11(1):47-54.
27. Billis A., Magna L.A. Inflammatory atrophy of the prostate, Prevalence and significance. Arch. Pathol. Lab. Med. 2003, 127(7):840-844.
28. Birdsey G.M., Dryden N.H., Amsellem V., Gebhardt F., et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 2008, 111(7):3498-3506.
29. Bismar T.A., Trpkov K. TMPRSS2-ERG gene fusion in transition zone prostate cancer. Mod. Pathol. 2010, 23(7):1040-1041.
30. Bismar T.A., Yoshimoto M., Vollmer R.T., Duan Q., et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int. 2011, 107(3):477-485.
31. Björkman M., Iljin K., Halonen P., Sara H., et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int. J Cancer. 2008, 123(12):2774-2781.
32. Bonkhoff H., Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate. 1996, 28(2):98-106.
33. Bonkhoff H., Stein U., Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate. 1994, 24(3):114-118.
34. Boormans J.L., Hermans K.G., Made A.C.J.Z-van der, Leenders G.J.H.L.van, et al. Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer. Eur. Urol. 2010, 57(5):830-835.
35. Bostwick D.G., Shan A., Qian J., Darson M., et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer. 1998, 83(9):1995-2002.
36. Braakhuis B.J.M., Tabor M.P., Kummer J.A., Leemans C.R., Brakenhoff R.H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003, 63(8):1727-1730.
37. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol. Clin. North Am. 2009, 36(4):403-415.
38. Carrère S., Verger A., Flourens A., Stehelin D., Duterque-Coquillaud M. Erg proteins, transcription factors of the ETS family, form homo, heterodimers and ternary complexes via two distinct domains. Oncogene. 1998, 16(25):3261-3268.
39. Carver B.S., Tran J., Gopalan A., Chen Z., et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Gen. 2009, 41(5):619-624.
40. Cattan V., Mercier N., Gardner J.P., Regnault V., et al. Chronic oxidative stress induces a tissue-specific reduction in telomere length in CAST/Ei mice. Free Rad. Biol. Med. 2008, 44(8):1592-5198.
41. Cavalieri E.L., Devanesan P., Bosland M.C., Badawi A.F., Rogan E.G. Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 2002, 23:329-333.
42. Cerveira N., Ribeiro F.R., Peixoto A., Costa V., et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006, 8(10):826-832.
43. Chai Y., Chipitsyna G., Cui J., Liao B., et al. c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells. Oncogene. 2001, 20(11):1357-1367.
44. Chaib H., MacDonald J.W., Vessella R.L., Washburn J.G., et al. Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. Genes Chromosomes Cancer 2003, 37(3):306-313.
45. Cheng L., Song S.Y., Pretlow T.G., Abdul-Karim F.W., et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J. Nat. Cancer Inst. 1998, 90(3):233-237.
46. Cheville J.C., Bostwick D.G. Postatrophic hyperplasia of the prostate. A histologic mimic of prostatic adenocarcinoma. Am. J Surg. Pathol. 1995, 19(9):1068-1076.
47. Chin K., Solorzano C.O., de Knowles D., Jones A., et al. In situ analyses of genome instability in breast cancer. Nat. Gen. 2004, 36(9):984-988.
48. Clark J., Merson S., Jhavar S., Flohr P., et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007, 26(18):2667-2673.
49. Collins A.T., Maitland N.J. Prostate cancer stem cells. Eur. J Cancer. 2006, 42(9):1213-1218.
50. Dai M.-J., Chen L.-L., Zheng Y.-B., Chen W., et al. Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer. Zhonghua yi xue za zhi. 2008, 88(10):669-673.
51. De Marzo A.M., DeWeese T.L., Platz E.A., Meeker A.K. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J. Cellular Biochem. 2004, 91(3):459-477.
52. De Marzo A.M., Marchi V.L., Epstein J.I., Nelson W.G. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J Pathol. 1999, 155(6):1985-1992.
53. De Marzo A.M., Nelson W.G., Meeker A.K., Coffey D.S. Stem cell features of benign and malignant prostate epithelial cells. J. Urol. 1998, 160(6 Pt 2):2381-2392.
54. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer. 2007, 7(4):256-269.
55. Demichelis F., Fall K., Perner S., Andrén O., et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007, 26(31):4596-4599.
56. Dhir R., Vietmeier B., Arlotti J., Acquafondata M., et al. Early identification of individuals with prostate cancer in negative biopsies. J. Urol. 2004, 171(4):1419-1423.
57. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Gen. 1998, 19(4):348-355.
58. Dijkman G.A., Debruyne F.M. Epidemiology of prostate cancer. Eur. Urol. 1996, 30(3):281-295.
59. Ellett F., Kile B.T., Lieschke G.J. The role of the ETS factor erg in zebrafish vasculogenesis. Mech. Dev. 2009, 126(3-4):220-229.
60. Faith D., Han S., Lee D.K., Friedl A., et al. P16 Is upregulated in proliferative inflammatory atrophy of the prostate. Prostate. 2005, 65(1):73-82.
61. Fan R., Kumaravel T.S., Jalali F., Marrano P., et al. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res. 2004, 64(23):8526-8533.
62. Feilotter H.E., Nagai M.A., Boag A.H., Eng C., Mulligan L.M. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene. 1998, 16(13):1743-1748.
63. FitzGerald L.M., Agalliu I., Johnson K., Miller M.A., et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 2008, 8:230.
64. Forusato B., Gao C.-L., Ravindranath L., Chen Y., McLeod D., Dobi A., Srivastava S., Petrovics G., Sesterhenn I.A. Mapping of TMPRSS2-ERG fusions in the context of miultifocal prostate cancer. Mod. Pathol. 2008, 21:67-75.
65. Foster C.S., Dodson A., Karavana V., Smith P.H., Ke Y. Prostatic stem cells. J. Pathol. 2002, 197(4):551-565.
66. Franks L.M. Atrophy and hyperplasia in the prostate proper. J. Pathol. Bacteriol. 1954, 68:617-621.
67. Gao C., Furusato B., McLeod D.G., Srivastava S., et al. Mapping of TMPRSS2-ERG fusion in Multi-Focal Prostate Cancer 2007, American Urological Association, Anaheim, California.
68. Garcia S.B., Park H.S., Novelli M., Wright N.A. Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. J. Pathol. 1999, 187(1):61-81.
69. Goldstein A.S., Huang J., Guo C., Garraway I.P., Witte O.N. Identification of a cell of origin for human prostate cancer. Science. 2010, 329(5991):568-571.
70. Gopalan A., Leversha M.A., Satagopan J.M., Zhou Q., et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009, 69(4):1400-1406.
71. Greene D.R., Wheeler T.M., Egawa S., Dunn J.K., Scardino P.T. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J. Urol. 1991, 146(4):1069-1076.
72. Guo C.C., Zuo G., Cao D., Troncoso P., Czerniak B.A. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod. Pathol. 2009, 22(7):866-871.
73. Han B., Mehra R., Lonigro R.J., Wang L., et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod. Pathol. 2009, 22(8):1083-1093.
74. Hanson J.A., Gillespie J.W., Grover A., Tangrea M.A., et al. Gene promoter methylation in prostate tumor-associated stromal cells. J. Nat. Cancer Inst. 2006, 98(4):255-261.
75. Hawksworth D., Ravindranath L., Chen Y., Furusato B., et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis. 2010, 13(4):311-315.
76. Hermans K.G., Alewijk D.C., van Veltman J.A., Weerden W., van, et al. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines. Genes Chromosomes Cancer. 2004, 39(3):171-184.
77. Holcomb I.N., Young J.M., Coleman I.M., Salari K., et al. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res. 2009, 69(19):7793-7802.
78. Houben J.M.J., Moonen H.J.J., Schooten F.J., Hageman G.J. Telomere length assessment: biomarker of chronic oxidative stress?. Free Rad. Biol. Med. 2008, 44(3):235-246.
79. Hsing A.W., Tsao L., Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer. 2000, 85(1):60-67.
80. Hughes S., Yoshimoto M., Beheshti B., Houlston R.S., et al. The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression. BMC Genomics. 2006, 7:65.
81. Iljin K., Wolf M., Edgren H., Gupta S., et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006, 66(21):10242-10246.
82. Isaacs J.T., Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate. 1989, 2:33-50.
83. Ishkanian A.S., Mallof C.A., Ho J., Meng A., et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate. 2009, 69(10):1091-1100.
84. Jemal A., Siegel R., Ward E., Murray T., et al. Cancer statistics, 2007. Cancer J. Clinicians 2007, 57(1):43-66.
85. Jenkins R.B., Qian J., Lieber M.M., Bostwick D.G. Detection of c-MYC oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 1997, 57(3):524-531.
86. Joshua A.M., Shen E., Yoshimoto M., Marrano P., et al. Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. Prostate. 2011, 71(7):778-790.
87. Joshua A.M., Vukovic B., Braude I., Hussein S., et al. Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer. Neoplasia. 2007, 9(1):81-89.
88. Kawata H., Ishikura N., Watanabe M., Nishimoto A., et al. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate. 2010, 70(7):745-754.
89. King J.C., Xu J., Wongvipat J., Hieronymus H., et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Gen. 2009, 41(5):524-526.
90. Kiviharju-af Hällström T.M., Jäämaa S., Mönkkönen M., Peltonen K., et al. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc. Nat. Acad. Sci. USA. 2007, 104(17):7211-7216.
91. Klezovitch O., Risk M., Coleman I., Lucas J.M., et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Nat. Acad. Sci. USA. 2008, 105(6):2105-2110.
92. Knudsen B.S., Vasioukhin V. Mechanisms of prostate cancer initiation and progression. Adv. Cancer Res. 2010, 109:1-50.
93. Koksal, I. T., Dirice, E., Yasar, D., Sanlioglu, A. D., et al. (2004). The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. 22, 4, 307-312.
94. Kristal A.R., Price D.K., Till C., Schenk J.M., et al. Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Prostate. 2010, 70(6):584-590.
95. Kruse E.A., Loughran S.J., Baldwin T.M., Josefsson E.C., et al. Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage. Proc. Nat. Acad. Sci. USA. 2009, 106(33):13814-13819.
96. Kwabi-Addo B., Giri D., Schmidt K., Podsypanina K., et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Nat. Acad. Sci. USA. 2001, 98(20):11563-11568.
97. Laczkó I., Hudson D.L., Freeman A., Feneley M.R., Masters J.R. Comparison of the zones of the human prostate with the seminal vesicle: morphology, immunohistochemistry, and cell kinetics. Prostate. 2005, 62(3):260-266.
98. Lapointe J., Li C., Giacomini C.P., Salari K., et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007, 67(18):8504-8510.
99. Lawson D.A., Witte O.N. Stem cells in prostate cancer initiation and progression. J. Clin. Invest. 2007, 117(8):2044-2050.
100. Lee K., Chae J.Y., Kwak C., Ku J.H., Moon K.C. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology. 2010, 76(5):1268. e7-1268.e13.
101. van Leenders G.J., Schalken J.A. Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. BJU Int. 2001, 88:35-42.
102. van Leenders G.J.L.H., Dukers D., Hessels D., Kieboom S.W.M., et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur. Urol. 2007, 52(2):455-463.
103. Leenders G.J.L.H., Gage W.R., Hicks J.L., Balken B., van, et al. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Amer. J. Pathol. 2003, 162(5):1529-1537.
104. Li L.-C., Carroll P.R., Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J. Natl. Cancer Inst. 2005, 97:103-115.
105. Liavåg I. The localization of prostatic carcinoma. An autopsy study. Scandinavian J. Urol. Nephrology. 1968, 2(2):65-71.
106. Litvinov I.V., De Marzo A.M., Isaacs J.T. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?. J. Clin. Endocrinol. Metabol. 2003, 88(7):2972-2982.
107. Liu A.Y., True L.D., LaTray L., Ellis W.J., et al. Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate. 1999, 40(3):192-199.
108. Liu W., Laitinen S., Khan S., Vihinen M., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 2009, 15(5):559-565.
109. Lu B., Maqsodi B., Yang W., McMaster G.K., et al. Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology. 2009, 74(5):1156-1161.
110. Lukacs R.U., Memarzadeh S., Wu H., Witte O.N. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell. 2010, 7(6):682-693.
111. Löbrich M., Jeggo P.A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat. Rev. Cancer. 2007, 7(11):861-869.
112. Macintosh C.A., Stower M., Reid N., Maitland N.J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res. 1998, 58(1):23-28.
113. Magi-Galluzzi C., Tsusuki T., Elson P., Simmerman K., et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate. 2011, 71(5):489-497.
114. Maitland N.J., Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int. 2005, 96(9):1219-1223.
115. Mao X., Yu Y., Boyd L.K., Ren G., et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 2010, 70(13):5207-5212.
116. McLaughlin F., Ludbrook V.J., Cox J., Carlowitz I.von, et al. Combined genomic and antisense analysis reveals that the transcription factor Erg is implicated in endothelial cell differentiation. Blood. 2001, 98(12):3332-3339.
117. McMenamin M.E., Soung P., Perera S., Kaplan I., et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999, 59(17):4291-4296.
118. Meeker A.K., Hicks J.L., Platz E.A., March G.E., et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res. 2002, 62(22):6405-6409.
119. Mehra R., Han B., Tomlins S.A., Wang L., et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007, 67(17):7991-7995.
120. Mehra R., Tomlins S.A., Yu J., Cao X., et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008, 68(10):3584-3590.
121. Meng A.X., Jalali F., Cuddihy A., Chan N., et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother. Oncol 2005, 76(2):168-176.
122. Miyagi Y., Sasaki T., Fujinami K., Sano J., et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod. Pathol. 2010, 23(11):1492-1498.
123. Montironi R., Hamilton P.W., Scarpelli M., Thompson D., Bartels P.H. Subtle morphological and molecular changes in normal-looking epithelium in prostates with prostatic intraepithelial neoplasia or cancer. Eur. Urol. 1999, 35(5-6):468-473.
124. Mosquera J.-M., Mehra R., Regan M.M., Perner S., et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin. Cancer Res. 2009, 15(14):4706-4711.
125. Mosquera J.-M., Perner S., Genega E.M., Sanda M., et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin. Cancer Res. 2008, 14(11):3380-3385.
126. Müller M., Rink K., Krause H., Miller K. PTEN/MMAC1 mutations in prostate cancer. Prostate Cancer Prostatic Dis. 2000, 3:S1-S32.
127. Nagle R.B., Ahmann F.R., McDaniel K.M., Paquin M.L., et al. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res. 1987, 47(1):281-286.
128. Nakayama M., Bennett C.J., Hicks J.L., Epstein J.I., et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture micr. Am. J. Pathol. 2003, 163(3):923-933.
129. Nupponen N.N., Visakorpi T. Molecular cytogenetics of prostate cancer. Microsc. Res. Tech. 2000, 51(5):456-463.
130. Nye J.A., Petersen J.M., Gunther C.V., Jonsen M.D., Graves B.J. Interaction of murine ETS-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif. Genes Dev. 1992, 6(6):975-990.
131. Ohigashi T., Mizuno R., Nakashima J., Marumo K., Murai M. Inhibition of Wnt signaling downregulates AKT activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate. 2005, 62(1):61-68.
132. Oikawa T., Yamada T. Molecular biology of the ETS family of transcription factors. Gene. 2003, 303:11-34.
133. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445(7123):106-110.
134. Paoloni-Giacobino A., Chen H., Peitsch M.C., Rossier C., Antonarakis S.E. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics 1997, 44(3):309-320.
135. Parsons J.K., Nelson C.P., Gage W.R., Nelson W.G., et al. GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate. 2001, 49(1):30-37.
136. Perner S., Mosquera J.-M., Demichelis F., Hofer M.D., et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 2007, 31(6):882-888.
137. Petrovics G., Liu A., Shaheduzzaman S., Furusato B., et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005, 24(23):3847-3852.
138. Pihan G.A., Purohit A., Wallace J., Malhotra R., et al. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res. 2001, 61(5):2212-2219.
139. Pihan G.A., Wallace J., Zhou Y., Doxsey S.J. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 2003, 63(6):1398-1404.
140. Potten C.S., Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development (Cambridge, England) 1990, 110(4):1001-1020.
141. Putzi M.J., De Marzo A.M. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000, 56(5):828-832.
142. Qian J., Wollan P., Bostwick D.G. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Human Pathol. 1997, 28(2):143-148.
143. Rajagopalan H., Nowak M.A., Vogelstein B., Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat. Rev. Cancer. 2003, 3(9):695-701.
144. Rajput A.B., Miller M.A., De Luca A., Boyd N., et al. Frequency of the TMPRSS2-ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J. Clin. Pathol. 2007, 60(11):1238-1243.
145. Randi A.M., Sperone A., Dryden N.H., Birdsey G.M. Regulation of angiogenesis by ETS transcription factors. Biochem. Soc. Trans. 2009, 37(6):1248-1253.
146. Reddy E.S., Rao V.N. ERG, an ETS-related gene, codes for sequence-specific transcriptional activators. Oncogene 1991, 6(12):2285-2289.
147. Reddy E.S., Rao V.N., Papas T.S. The erg gene: a human gene related to the ETS oncogene. Proc. Nat. Acad. Sci. USA 1987, 84(17):6131-6135.
148. Reid A.H.M., Attard G., Ambroisine L., Fisher G., et al. Molecular characterisation of ERG. ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Brit. J. Cancer 2010, 102(4):678-684.
149. Ribeiro F.R., Diep C.B., Jerónimo C., Henrique R., et al. Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer 2006, 45(2):154-163.
150. Richardson G.D., Robson C.N., Lang S.H., Neal D.E., et al. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 2004, 3539-3545.
151. Richter T., Proctor C. The role of intracellular peroxide levels on the development and maintenance of telomere-dependent senescence. Exp. Gerontol. 2007, 42(11):1043-1052.
152. Ruijter E.T., Kaa C.A., Schalken J.A., Debruyne F.M., Ruiter D.J. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J. Pathol. 1996, 180(3):295-299.
153. Ruijter E.T., Miller G.J., Kaa C.A., van de Bokhoven A.van, et al. Molecular analysis of multifocal prostate cancer lesions. J. Pathol. 1999, 188(3):271-277.
154. Ruska K.M., Sauvageot J., Epstein J.I. Histology and cellular kinetics of prostatic atrophy. Am. J. Surg. Pathol. 1998, 22(9):1073-1077.
155. Sakr W.A., Grignon D.J., Crissman J.D., Heilbrun L.K., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In vivo (Athens, Greece) 1994, 8(3):439-443.
156. Sakr W.A., Haas G.P., Cassin B.F., Pontes J.E., Crissman J.D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 1993, 150(2 Pt 1):379-385.
157. Saramäki O.R., Harjula A.E., Martikainen P.M., Vessella R.L., et al. TMPRSS2-ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin. Cancer Res. 2008, 14(11):3395-3400.
158. Saramaki O., Visakorpi T. Chromosomal aberrations in prostate cancer. Frontiers Biosc. 2007, 12:3287-3301.
159. Sarker D., Reid A.H.M., Yap T.A., Bono J.S.de Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 2009, 15(15):4799-4805.
160. Sato H., Minei S., Hachiya T., Yoshida T., Takimoto Y. Fluorescence in situ hybridization analysis of c-MYC amplification in stage TNM prostate cancer in Japanese patients. Int. J. Urol. 2006, 13(6):761-766.
161. Sato Y. Role of ETS family transcription factors in vascular development and angiogenesis. Cell Struct. Funct. 2001, 26(1):19-24.
162. Schayek H., Haugk K., Sun S., True L.D., et al. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin. Cancer Res. 2009, 15(5):1558-1565.
163. Schmitz M., Grignard G., Margue C., Dippel W., et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int. J. Cancer 2007, 120(6):1284-1292.
164. Schulz W.A., Ingenwerth M., Djuidje C.E., Hader C., et al. Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation. BMC Cancer 2010, 10:505.
165. Schweizer L., Rizzo C.A., Spires T.E., Platero J.S., et al. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol. 2008, 9:4.
166. Shah R., Mucci N.R., Amin A., Macoska J.A., Rubin M.A. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander?. Am. J. Pathol. 2001, 158(5):1767-1773.
167. Signoretti S., Loda M. Defining cell lineages in the prostate epithelium. Cell Cycle (Georgetown, Tex.) 2006, 5(2):138-141.
168. Singh S., Barrett J., Sakata K., Tozer R.G., Singh G. ETS proteins and MMPs: partners in invasion and metastasis. Current Drug Targ. 2002, 3(5):359-367.
169. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63(18):5821-5828.
170. Sircar K., Yoshimoto M., Monzon F.A., Koumakpayi I.H., et al. PTEN genomic deletion is associated with p-AKT and AR signalling in poorer outcome, hormone refractory prostate cancer. J. Pathol. 2009, 218(4):505-513.
171. Slaughter D.P., Southwick H.W., Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6(5):963-968.
172. Squire J.A. TMPRSS2-ERG and PTEN loss in prostate cancer. Nat. Genet. 2009, 41(5):509-510.
173. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457(7231):910-914.
174. Stott S.L., Lee R.J., Nagrath S., Yu M., et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci. Trans. Med. 2010, 2(25):25ra23.
175. Sun C., Dobi A., Mohamed A., Li H., et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008, 27(40):5348-5353.
176. Sun Q.-P., Li L.-Y., Chen Z., Pang J., et al. Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study. J. Mol. Diagnostics 2010, 12(5):718-724.
177. Sun Y., Gao W.-Q. Human prostate cancer stem cells: new features unveiled. Asian J. Androl. 2011, 13(3):355-356.
178. Tang D.G., Patrawala L., Calhoun T., Bhatia B., et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol. Carcinogen. 2007, 46(1):1-14.
179. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18(1):11-22.
180. Terry S., Yang X., Chen M.-W., Vacherot F., Buttyan R. Multifaceted interaction between the androgen and WNT signaling pathways and the implication for prostate cancer. J. Cellular Biochem. 2006, 99(2):402-410.
181. The American Cancer Society, 2011 "." http://www.cancer.org/Research/CancerFactsFigures/index.
182. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., Menon A., Jing X., Cao Q., Han B., Yu J., Wang L., Montie J.E., Rubin M.A., Pienta K.J., Roulston D., Shah R.B., Varambally S., Mehra R., Chinnaiyan A.M. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448(7153):595-599.
183. Tomlins S.A., Laxman B., Varambally S., Cao X., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10(2):177-188.
184. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310(5748):644-648.
185. Trojanowska M. ETS factors and regulation of the extracellular matrix. Oncogene 2000, 19(55):6464-6471.
186. Vaarala M.H., Porvari K., Kyllönen A., Lukkarinen O., Vihko P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int. J. Cancer 2001, 94(5):705-710.
187. Verger A., Buisine E., Carrère S., Wintjens R., et al. Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation. J. Bio. Chem. 2001, 276(20):17181-17189.
188. Verhagen P.C.M.S., Duijn P.W., Hermans K.G.L., Looijenga L.H.J., et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J. Pathol. 2006, 208(5):699-707.
189. Verhagen A.P., Ramaekers F.C., Aalders T.W., Schaafsma H.E., et al. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res. 1992, 52(22):6182-6187.
190. Vis A.N., Schröder F.H. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int. 2009, 104(4):438-448.
191. Vukovic B., Park P.C., Al-Maghrabi J., Beheshti B., et al. Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene 2003, 22(13):1978-1987.
192. Wang J., Cai Y., Ren C., Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006, 66(17):8347-8351.
193. Wang J., Cai Y., Yu W., Ren C., et al. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008, 68(20):8516-8524.
194. Wang X., Kruithof-de Julio M., Economides K.D., Walker D., et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461(7263):495-500.
195. Wang Y., Romigh T., He X., Orloff M.S., et al. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Human Mol. Gen. 2010, 19(22):4319-4329.
196. Watson S.K., Woolcock B.W., Fee J.N., Bainbridge T.C., et al. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization. Prostate 2009, 69(9):961-975.
197. Wilson S., Greer B., Hooper J., Zijlstra A., et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem. J. 2005, 388(Pt 3):967-972.
198. Wise A.M., Stamey T.A., McNeal J.E., Clayton J.L. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002, 60(2):264-269.
199. Yoshimoto M., Cunha I.W., Coudry R.A., Fonseca F.P., et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br. J. Cancer 2007, 97(5):678-685.
200. Yoshimoto M., Cutz J.-C., Nuin P.A.S., Joshua A.M., et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genetics Cytogen. 2006, 169(2):128-137.
201. Yoshimoto M., Joshua A.M., Chilton-Macneill S., Bayani J., et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006, 8(6):465-469.
202. Yoshimoto M., Joshua A.M., Cunha I.W., Coudry R.A., et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod. Pathol. 2008, 21(12):1451-1460.
203. Yoshimoto M., Ludkovski O., Bayani J., Graham C., et al. Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion. Genes Chromosomes and Cancer 2007, 46(9):861-863.
204. Yu Y.P., Landsittel D., Jing L., Nelson J., et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 2004, 22(14):2790-2799.
205. Zha S., Gage W.R., Sauvageot J., Saria E.A., et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 2001, 61(24):8617-8623.
206. Zhang S., Pavlovitz B., Tull J., Wang Y., et al. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization. Diagn. Mol. Pathol. 2010, 19(3):151-156.
207. Zhang S., Yu D. PI(3)King apart PTEN's role in cancer. Clin. Cancer Res. 2010, 16(17):4325-4330.
208. Zvereva M.I., Shcherbakova D.M., Dontsova O.A. Telomerase: structure, functions, and activity regulation. Biochem. Biokhimiia 2010, 75(13):1563-1583.